Genentech and Nvidia in strategic drug discovery and development AI pact

Genentech, a member of the Roche Group (RHHBY) announced a multi-year strategic research collaboration with NVIDIA (NVDA) that couples Genentech’s artificial intelligence AI capabilities, extensive biological and molecular datasets, and research expertise with NVIDIA’s world-leading accelerated computing capabilities and AI to speed up drug discovery and development. The collaboration is designed to significantly enhance Genentech’s advanced AI research programs by transforming its generative AI models and algorithms into a next-generation AI platform, expediting the discovery and delivery of novel therapies and medicines to people. The companies will join forces to accelerate and optimize Genentech’s proprietary machine learning ML algorithms and models on NVIDIA DGX Cloud, which provides a training-as-a-service platform built on dedicated NVIDIA AI supercomputing and software, including NVIDIA BioNemo for generative AI applications in drug discovery. NVIDIA will share its computing expertise with Genentech’s teams of computational scientists with the goal of optimizing and scaling Genentech’s models, and in that process, may improve or enhance NVIDIA’s platforms.